Biotechnology and Life Sciences Investment in Turkey: Opportunities and Regulatory Guide

Turkey’s biotechnology and life sciences sector has experienced remarkable growth in recent years, driven by a young and educated population, strategic geographic positioning, and a government committed to building a knowledge-based economy. For foreign investors seeking new frontiers in biotech, Turkey offers a compelling combination of cost advantages, skilled talent, and an expanding domestic market.

Why Turkey for Biotechnology and Life Sciences?

Strategic Advantages

Turkey sits at the crossroads of Europe, Asia, and the Middle East, providing access to a combined market of over 1.5 billion people within a four-hour flight radius. This geographic advantage extends to clinical trials, pharmaceutical distribution, and life sciences R&D operations.

Key factors driving biotech investment in Turkey:

• Young, educated workforce: Over 200,000 STEM graduates annually, with growing specialization in molecular biology, genetics, and biomedical engineering
• Cost-competitive operations: R&D and manufacturing costs significantly lower than Western Europe while maintaining high quality standards
• Large domestic market: A population of over 85 million with increasing healthcare expenditure
• Government commitment: National strategies targeting biotechnology as a priority sector for 2026-2030

Market Overview

Turkey’s pharmaceutical and life sciences market has grown to become one of the largest in Europe and the MENA region. The country ranks among the top 20 pharmaceutical markets globally, with domestic production meeting a significant share of local demand.

The biotechnology subsector is still emerging but growing rapidly, with increasing activity in:

• Biosimilars and biologic drug manufacturing
• Agricultural biotechnology
• Industrial biotechnology and bioplastics
• Genomics and personalized medicine
• Medical device innovation

Regulatory Framework for Biotech Companies

Company Formation

Foreign investors can establish biotech companies in Turkey under the same legal structures available to domestic investors. The most common options include:

• Limited Liability Company (LLC): Suitable for small to mid-sized biotech startups and R&D operations
• Joint Stock Company (JSC): Preferred for larger operations, especially those planning to attract venture capital or pursue an eventual IPO

There are no restrictions on foreign ownership in the biotechnology sector, and 100% foreign-owned companies are permitted.

Licensing and Permits

Biotech companies in Turkey must comply with regulations overseen by several key authorities:

• Turkish Medicines and Medical Devices Agency (TITCK): Regulates pharmaceuticals, medical devices, clinical trials, and biologic products
• Ministry of Agriculture and Forestry: Oversees agricultural biotechnology and biosafety regulations
• Ministry of Industry and Technology: Manages technopark approvals and R&D incentive programs
• Turkish Patent and Trademark Office (TURKPATENT): Handles biotech patent filings and intellectual property protection

Biosafety Regulations

Turkey’s Biosafety Law (No. 5977) regulates genetically modified organisms (GMOs) and their products. While the law restricts GMO cultivation for commercial purposes, it allows:

• Importation of GMO products for animal feed (subject to approval)
• Contained-use research on GMOs in certified laboratories
• Clinical research involving genetic therapies under strict oversight

Foreign investors in agricultural biotech should carefully evaluate the biosafety regulatory landscape before entering the market.

Clinical Trials Regulation

Turkey has become an increasingly attractive destination for clinical trials, thanks to:

• A genetically diverse population beneficial for multi-ethnic studies
• Growing clinical trial infrastructure with experienced investigators
• Regulatory alignment with ICH-GCP (International Council for Harmonisation - Good Clinical Practice) guidelines
• Competitive patient recruitment timelines

The TITCK oversees clinical trial approvals, with a review process that typically takes 45-60 days. Phase I through Phase IV trials are conducted across Turkey’s network of university hospitals and research centers.

Investment Incentives for Biotech Companies

R&D Law Incentives (Law No. 5746)

Biotech companies conducting R&D in Turkey benefit from generous incentives under the R&D Law:

• Income tax exemption: 100% tax exemption on wages of R&D personnel (with social security contribution support)
• Corporate tax deduction: Additional 100% deduction on qualifying R&D expenditures
• Stamp duty exemption: On documents related to R&D activities
• VAT exemption: On domestically sourced machinery and equipment for R&D

Technology Development Zones (Technoparks)

Turkey operates over 90 technoparks, many of which host biotech and life sciences companies. Benefits include:

• Corporate tax exemption on income generated from software and R&D activities within the zone
• VAT exemption on deliveries of application software
• Income tax exemption for R&D personnel
• Proximity to universities and research institutions

Notable technoparks with biotech focus include:

• ITU ARI Teknokent (Istanbul)
• ODTU Teknokent (Ankara)
• Ege University Science and Technology Center (Izmir)
• Erciyes Technopark (Kayseri) - with a dedicated life sciences cluster

Strategic Investment Incentives

Large-scale biotech investments may qualify for Turkey’s Strategic Investment Incentive Scheme, which offers:

• Corporate tax reduction (up to 90% of the investment amount)
• VAT exemption on machinery and equipment
• Customs duty exemption on imported equipment
• Interest rate support on loans
• Land allocation at reduced or no cost
• Energy cost support for up to 10 years

To qualify, the investment must address import dependency in a sector deemed strategically important. Biosimilars production, API (Active Pharmaceutical Ingredient) manufacturing, and advanced medical device production typically qualify.

KOSGEB Support Programs

Small and medium-sized biotech enterprises can access support through KOSGEB (Small and Medium Enterprises Development Organization):

• Startup grants for innovative biotech companies
• R&D and innovation support programs
• International market entry support
• Technology-focused entrepreneurship programs

Key Subsectors and Opportunities

Biosimilars Manufacturing

Turkey has positioned itself as a regional hub for biosimilar production. The government actively encourages domestic manufacturing of biologic drugs to reduce import dependency. Opportunities exist in:

• Monoclonal antibody production
• Insulin biosimilars
• Oncology biosimilars
• Contract manufacturing (CMO/CDMO) services

Genomics and Precision Medicine

With the establishment of the Turkish Genome Project and increasing investment in genomics infrastructure, opportunities are growing in:

• Genetic testing and diagnostics
• Pharmacogenomics services
• Bioinformatics platforms
• Gene therapy research

Medical Devices and Diagnostics

Turkey’s medical device market continues to expand, with increasing local production. Foreign investors can benefit from:

• A large domestic hospital network (both public and private)
• Export potential to Central Asia, Middle East, and Africa
• Government procurement preferences for locally manufactured products
• EU regulatory alignment (CE marking recognized)

Agricultural Biotechnology

While GMO cultivation restrictions limit some activities, opportunities exist in:

• Seed technology and plant breeding
• Biopesticides and biofertilizers
• Animal genetics and livestock improvement
• Agricultural genomics research

Intellectual Property Protection

Turkey’s IP framework for biotechnology has strengthened significantly:

• Patent protection: Biotech inventions, including gene sequences, proteins, and bioprocesses, are patentable under Turkish law (Industrial Property Law No. 6769)
• Data exclusivity: 6 years of data exclusivity for original pharmaceuticals, with additional protections for biologics
• Patent term extension: Available for pharmaceutical patents delayed by regulatory approval processes
• TURKPATENT: Active member of PCT (Patent Cooperation Treaty), facilitating international patent filings

Trade Secrets and Know-How

Biotech companies often rely heavily on trade secret protection. Turkish Commercial Code and competition law provide protections for:

• Proprietary manufacturing processes
• Cell lines and biological materials
• Clinical trial data
• Proprietary algorithms and bioinformatics tools

Workforce and Talent

Turkey produces a significant number of life sciences graduates annually. Key talent pools include:

• Molecular biology and genetics programs at over 50 universities
• Biomedical engineering departments producing skilled device engineers
• Growing bioinformatics and computational biology expertise
• Experienced clinical research professionals

Foreign companies can sponsor work permits for international talent, including researchers and executives. R&D personnel working in technoparks benefit from income tax exemptions, making Turkey cost-competitive for assembling biotech research teams.

Setting Up a Biotech Operation: Practical Steps

1. Market analysis and regulatory assessment: Evaluate subsector regulations and identify applicable incentives
2. Company incorporation: Register an LLC or JSC (typically 3-5 business days)
3. Technopark application: Apply for space in a relevant technology development zone
4. R&D center certification: If operating outside a technopark, apply for R&D center status (minimum 15 full-time R&D employees required)
5. Licensing and permits: Obtain sector-specific licenses from TITCK or relevant authorities
6. Incentive applications: Apply for investment incentives through the Ministry of Industry and Technology
7. Talent recruitment: Build the team, leveraging university partnerships and industry networks

Challenges to Consider

While Turkey offers significant opportunities, investors should be aware of:

• Currency volatility: The Turkish Lira has experienced fluctuations; hedging strategies are advisable
• Regulatory evolution: The biotech regulatory framework is still maturing in certain areas
• GMO restrictions: Limitations on GMO cultivation may affect agricultural biotech plans
• Infrastructure gaps: Some specialized lab equipment and reagents may need to be imported

Conclusion

Turkey’s biotechnology and life sciences sector represents a significant growth opportunity for foreign investors. With generous R&D incentives, a large and growing domestic market, competitive costs, and strategic geographic positioning, the country is well-placed to become a regional biotech hub.

Whether you are looking to establish a biosimilars manufacturing facility, set up a clinical research operation, or launch a genomics startup, Turkey offers the infrastructure, talent, and incentive framework to support your investment.

---

Ready to explore biotechnology investment opportunities in Turkey? FDI Consultancy provides end-to-end support for foreign investors entering Turkey’s life sciences sector, from regulatory guidance and company formation to incentive applications and talent acquisition. Contact us to discuss your investment plans.